Format

Send to

Choose Destination
Lancet Oncol. 2014 Aug;15(9):e395-403. doi: 10.1016/S1470-2045(14)70011-7.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Author information

1
Department of Neurology, University Hospital Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch.
2
Neurooncology Unit, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
3
Bristol Haematology and Oncology Centre, Bristol, UK.
4
Department of Neurosurgery, University of Munich LMU, Munich, Germany.
5
Department of Oncology, University Hospital Zurich, Zurich, Switzerland.
6
Department of Neuroradiology, Scientific Institute San Raffaele Hospital and University Vita-Salute San Raffaele, Milan, Italy.
7
Département de Radiotherapie, Institut Claudius Regaud, Toulouse, France.
8
Neurooncologie Adulte et Pédiatrique, Centre Léon Bérard, Lyon, France.
9
Regional Cancer Center Stockholm Gotland and Department of Radiation Sciences and Oncology, Umeå University Hospital, Sweden.
10
Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Canyet sn, Badalona, Spain.
11
Aix-Marseille Université, Department of Neuro-Oncology, CHU Timone, Marseilles, France.
12
Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel.
13
Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; German Cancer Consortium, partner site Essen/Düsseldorf, Düsseldorf, Germany.
14
Department of Neuro-Oncology, University Hospital, Turin, Italy.
15
Department of Neurooncology, Neurology Clinic & National Center for Tumor Diseases, University Hospital Heidelberg, Germany; German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

Erratum in

Abstract

This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

PMID:
25079102
DOI:
10.1016/S1470-2045(14)70011-7
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center